JPRN-UMIN000002044
尚未招募
2 期
The Utility of PET/CT in Erlotinib treatment for Non-Small Cell cancer - The Utility of PET/CT in Erlotinib treatment for Non-Small Cell cancer
Department of Respiratory Medicine, Allergy and Rheumatic Diseases, Osaka University Graduate School of Medicine0 个研究点目标入组 20 人开始时间: 2009年6月8日最近更新:
概览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- Department of Respiratory Medicine, Allergy and Rheumatic Diseases, Osaka University Graduate School of Medicine
- 入组人数
- 20
概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1\)History of radiation therapy for primary site 2\)Severe infection 3\)Bowel obstruction 4\)Interstitioal pneumonia or lung fibrosis 5\)History of any thoracic radiation therapy 6\)Active concomitant malignancy 7\)Sever heart disease 8\)No regulatory condition because of psychological disease 9\)Pregnant women or somen willing child\-bearing 10\)inadequate condition siagnosed by primary physician
研究者
相似试验
Unknown
不适用
The Role of Positron Emission Tomography (PET) During Erlotinib Treatment for Non-small Cell Lung CancerErlotinibLung CancerNCT01000428Asan Medical Center34
招募中
不适用
High-sensitivity imaging of erlotinib in resected non-small-cell lung cancerJPRN-UMIN000009745Department of Internal Medicine Division of Medical Oncology & Respiratory Medicine Shimane University Faculty of Medicine1
已完成
不适用
Evaluation of efficacy of erlotinib in patients with untreated, EGFR mutation positive, untreated-locally advanced NSCLC.ntreated, EGFR mutation positive, untreated-locally advanced NSCLC.JPRN-UMIN000011467agasaki Thoracic Oncology Group10
招募中
2 期
A phase II study of erlotinib for patients with pretreated non-small cell lung cancer with brain metastasis and sensitive EGFR mutations.on-small cell lung cancerJPRN-UMIN000002861Shizuoka General Hospital Respiratory center24
进行中（未招募）
不适用
A Pilot Study of Erlotinib and Temsirolimus in Patients with Advanced Non-small Cell Lung Cancer After Failure of at Least 1 Prior Platinum-based TreatmentSCLCEUCTR2009-017101-11-ATMUW, Klinik für Innere Medizin I, Onkologie20